Search results
Results from the WOW.Com Content Network
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. The popular weight-loss drug Zepbound can now be used to treat sleep ...
Popular weight loss drug could treat sleep apnea, company says. Justin Boggs. April 17, 2024 at 9:15 AM. A closed box of the starter 2.5mg dose of Eli Lilly’s weight loss injectable, Zepbound.
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
Therefore, tirzepatide’s ability to significantly aid in weight loss can play a critical role in reducing one of the primary causes of sleep apnea. As of now, the weight loss aspect of the drug ...
Spironolactone can cause hyperkalemia, or high blood potassium levels. [111] Rarely, this can be fatal. [111] Of people with heart disease prescribed typical dosages of spironolactone, 10 to 15% develop some degree of hyperkalemia, and 6% develop severe hyperkalemia. [111] At a higher dosage, a rate of hyperkalemia of 24% has been observed. [119]
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
The most effective treatment is weight loss, but this may require bariatric surgery to achieve. [3] Weight loss of 25 to 30% is usually required to resolve the disorder. [3] The other first-line treatment is non-invasive positive airway pressure (PAP), usually in the form of continuous positive airway pressure (CPAP) at night.
Without treatment, the sleep deprivation and lack of oxygen caused by sleep apnea increases health risks such as cardiovascular disease, aortic disease (e.g. aortic aneurysm), [165] high blood pressure, [166] [167] stroke, [168] diabetes, clinical depression, [169] weight gain, obesity, [66] and even death.